This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

GencaroTM Pharmacogenetic Effect Paper Published In Peer Reviewed Journal PLOS ONE

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that the paper "Combinatorial pharmacogenetic interactions of bucindolol (Gencaro) and beta-1, alpha-2c adrenergic receptor polymorphisms” was published in PLOS ONE ( http://dx.plos.org/10.1371/journal.pone.0044324), an international, peer-reviewed, open-access, online publication.

Analyses in the paper demonstrate that two previously described adrenergic receptor polymorphisms that have been shown to pharmacogenetically interact with the anti-adrenergic agent and beta-blocker Gencaro (bucindolol hydrochloride) appeared to behave in specific, pharmacologically-determined ways when individual genetic monotypes are combined.

The paper details the combined research efforts of three leading cardiologists and/or pharmacogeneticists:

  • Christopher O'Connor, M.D., Professor of Medicine, Director of the Duke Heart Center, Duke University Medical Center, Lead Author of the paper;
  • Steven Liggett, M.D., Associate Vice President for Personalized Medicine, Morsani College of Medicine University of South Florida in Tampa, a senior author of the paper whose laboratory discovered and characterized the two adrenergic receptor polymorphisms; and,
  • Michael Bristow, M.D., Ph.D., President and CEO of ARCA biopharma and Professor of Medicine (Cardiology) at the University of Colorado Anschutz Medical Campus, the senior author of the paper in whose academic laboratory the mechanism for the described pharmacogenetic interaction was discovered and characterized.

Dr. Bristow commented, “These data demonstrate that combinatorial pharmacogenetic interactions may be used to increase the predictive power of genetic biomarkers to identify subpopulations of patients that appear to respond either better or worse than the general population of patients. In the case of Gencaro, in this review of study data, adrenergic receptor combinatorial pharmacogenetics appear to identify a substantial subpopulation of patients in the study, approximately 45-50% of the total, in which responses appear to exceed outcomes reported for other studies with other beta-blockers in U.S. heart failure populations. These pharmacogenetic findings also identify a smaller subpopulation, approximately 10-15%, where the drug did not appear to be useful in preventing heart failure in this study. The ability to identify these subpopulations may allow for more efficient drug development and potentially improved targeted therapies for cardiovascular patients, if regulatory approval is obtained."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,070.06 -28.39 -0.17%
S&P 500 1,999.37 -4.00 -0.20%
NASDAQ 4,590.68 +10.4090 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs